# Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy

> **NCT04254913** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 6 (actual)

## Conditions studied

- Japanese Patients With ALS

## Interventions

- **DRUG:** MT-1186

## Key facts

- **NCT ID:** NCT04254913
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-24
- **Primary completion:** 2020-04-16
- **Final completion:** 2020-04-22
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04254913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04254913, "Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04254913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*